A clinical pharmacological (Phase I) Study of APTA-2217 in healthy elderly male volunteers (under fasting conditions, single oral dose).

Study identifier:APTA-2217-HP-02

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Official Title: *Please Note* The Study you are attempting to view was originally sponsored by Tanabe and acquired from Takeda by AstraZeneca and was disclosed initially by Takeda per their Transparency Policies.. More information regarding this study may be available by contacting [email protected].

Medical condition

Chronic Obstructive Pulmonary Disease

Phase

Healthy volunteers

Yes

Study drug

Sex

Male

Actual Enrollment

Study type

Interventional

Age

65 Years - 80 Years

Date

Study Start Date: 01 Sept 2003

Primary Completion Date: -

Study Completion Date: 01 Oct 2003

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jun 2016 by Tanabe

Collaborators

Altana Pharma AG

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

Documents available

APTA-2217-HP-02-RDS-2014-10-26.pdf
Download
Trial Results Summaries
Available here